Research programme: somatostatin type 2 receptor antagonists - Zucara Therapeutics

Drug Profile

Research programme: somatostatin type 2 receptor antagonists - Zucara Therapeutics

Alternative Names: PRL-2903

Latest Information Update: 25 Oct 2016

Price : $50

At a glance

  • Originator University of Toronto
  • Developer Zucara Therapeutics
  • Class Peptides
  • Mechanism of Action Somatostatin receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hypoglycaemia

Most Recent Events

  • 14 Oct 2016 Zucara Therapeutics enters into a licensing agreement with The Centre for Drug Research and Development for access to certain patented compounds
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top